Impact of Chronic Obstructive Pulmonary Disease on Long-Term Outcome in Patients with Coronary Artery Disease Undergoing Percutaneous Coronary Intervention
Table 1
Baseline patient characteristics.
Variable
No COPD ()
COPD ()
value
Clinical characteristics
Age
63.9 ± 11.3
66.4 ± 12.4
<0.0001
Male, number (%)
1368 (64.3)
149 (64.0)
0.93
Body mass index (kg)
30.1 ± 5.8
30.3 ± 6.8
0.91
Diabetes mellitus, number (%)
547 (25.8)
70 (30.4)
0.01
Hypertension, number (%)
1440 (68.8)
169 (73.5)
0.02
Current smoking, number (%)
279 (14.8)
38 (19.1)
0.04
Hyperlipidemia, number (%)
1459 (80.6)
154 (84.6)
0.37
MI, number (%)
811 (38.5)
99 (43.4)
0.02
F/H CAD, number (%)
606 (36.5)
57 (34.1)
0.55
EF_le40, number (%)
128 (6.0)
19 (8.2)
0.04
CHF, number (%)
190 (9.2)
48 (22.02)
<0.0001
Renal Failure, number (%)
141 (6.6)
20 (8.6)
0.07
Laboratory characteristics
White blood cells, median (, )
7.5 (6.1, 9.3)
8.1 (6.6, 10.3)
0.0002
Hemoglobin (g/dL), median (, )
13 (12, 14.1)
12.9 (12, 14.1)
0.17
Platelet (g/l), median (, )
210 (176, 250)
219 (180, 260)
0.20
BUN
18 (14, 22)
18 (14, 24)
0.27
Cr (mg/dl), median (, )
1.1 (1, 1.3)
1.1 (1.0, 1.2)
0.47
TC (mg/dl), median (, )
186 (158, 220)
179 (158, 214)
0.13
TG (mg/dl), median (, )
147 (102, 208)
141 (93, 190)
0.17
LDL (mg/dl), median (, )
110 (85, 138)
104 (82, 129)
0.03
HDL, median (, )
43 (36, 52)
43 (37, 54)
0.13
Left main disease, number (%)
39 (1.8)
5 (2.2)
0.74
Emergent PCI
263 (12)
29 (13)
0.87
DES
549 (26)
53 (22.8)
0.31
Use of medications at discharge
Aspirin, number (%)
1954 (93)
201 (87)
0.003
Clopidogrel, number (%)
1053 (50)
99 (43)
0.04
ACEI/ARB, number (%)
1014 (48)
119 (51)
0.34
CCBs, number (%)
571 (27)
88 (38)
0.001
Beta-blockers, number (%)
1596 (75)
169 (72)
0.36
Statins, number (%)
1585 (75)
182 (78)
0.25
MI, myocardial infarction; F/H CAD, family history of coronary artery disease; BUN, blood urea nitrogen; TG, triglyceride; total cholesterol, TC; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; PCI, percutaneous coronary intervention; DES, drug eluting stent; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blockers. CCBs, calcium-channel blockers.